FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

The U.S. Food and Drug Administration recently approved the first commercially available positron emission tomography (PET) imaging agent targeting the prostate-specific membrane antigen (PSMA). This represents the culmination of 25 years of work for Martin Pomper, M.D., Ph.D., a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Read more about this innovation here.

Recent Posts
The Best Way to Take A Pill, According to Science 8 Ways to Lose Belly Fat and Live a Healthier Life Sunglasses Are More Than Just a Fashion Accessory Liquid Biopsy Detects DNA Markers in Advanced Breast Cancer Within Five Hours Living Better with Brain Cancer DNA Shed From Colon Cancers Into Bloodstream Guide Chemotherapy New Treatment Protocols for Early Stage Lung Cancer Johns Hopkins Medicine Researchers Awarded Nearly $8 Million from Break Through Cancer Foundation The Importance of Cancer Screening